Biomarker ID | 583 |
PMID | 21240253 |
Year | 2010 |
Biomarker | β-microseminoprotein (MSMB) |
Biomarker Basis | Expression Based |
Biomolecule | Protein |
Source | Tissue |
Subjects | Humans |
Regulation | increased expression with decreased biochemical recurrence-free survival |
Odds Ratio/Hazard Ratio/Relative Risk | Univariate Analysis: HR: 0.468; (95% CI: 0.394-0.556); Multivariate Analysis: HR: 0.710 (95% CI :0.578-0.872); |
Effect on Pathways | Oncostatin M |
Experiment | Biochemical Recurrence Vs No Biochemical Recurrence |
Type of Biomarker | Prognostic |
Cohort | Tissue specimens were available from 3268 patients, undergoing radical prostatectomy were taken. Full follow-up data were available for 2460 patients, of which 620 developed biochemical recurrence. |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p<0.001 |
Method Used | Immunohistochemistry |
Clinical | No |
Remarks | Univariate Analysis; Biochemical recurrence was defined as post-operative PSA values of >=0.1ng/ ml with a confirmatory value. |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | MSMB |